Assessment of facility performance during mass treatment of chronic hepatitis C in Egypt: Enablers and obstacles

Shousha, Hend Ibrahim; Said, Mohamed; El-Akel, Wafaa; Shafei, El; Esmat, Gamal; Waked, Emam; El-Sayed, Manal Hamdy; Doss, Wahid; elrazky, Maysa; Mehrez, Mai; Hassany, Mohamed; zeyada, Dina; Anis, Mahmoud; Alserafy, Magdy

doi:10.1016/j.jiph.2020.05.008

Cited by 9 publications

(5 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…monitored at the regional and center levels. 37 Additionally, it allowed for instant troubleshooting to overcome logistical challenges. The integration of health information systems reduced paperwork costs, which accounted for 65% of patients' out-of-pocket costs.…”

Section: Political Streammentioning

confidence: 99%

Egypt's Ambitious Strategy to Eliminate Hepatitis C Virus: A Case Study

Hassanin

Kamel

Waked

et al. 2021

Glob Health Sci Pract

View full text Add to dashboard Cite

show abstract

Section: Political Streammentioning

confidence: 99%

Egypt's Ambitious Strategy to Eliminate Hepatitis C Virus: A Case Study

Hassanin

Kamel

Waked

et al. 2021

Glob Health Sci Pract

View full text Add to dashboard Cite

show abstract

“…The patients received different treatment regimens according to the chronological changes of the drugs available in the treatment centers of the NCCVH affiliated to the Egyptian Ministry of Health and the Population. The treatment-experienced patients were managed by separate clinics within the NCCVH centers with specialized consultants 6 . Within this study, patients who received the SOF/VEL/VOX combination, with and without RBV, showed the least adverse event profile and better SVR-12 rates.…”

Section: Discussionmentioning

confidence: 99%

“…As reported in 2008, Egypt had the highest HCV burden globally 2 with genotype 4 affecting more than 94% of patients 3 , 4 . In 2015, the seroprevalence of HCV infection had declined to 6.3% 5 with an estimated overall prevalence reduction of 30%, particularly after the introduction of direct-acting antiviral therapy (DAAs) 6 . By 2018, more than two million people with CHC received DAAs (40% of the infected population), with SVR rates over 90% 7 .…”

Section: Introductionmentioning

confidence: 99%

Three regimens for re-treatment failure of Sofosbuvir-based therapy for chronic hepatitis-C genotype-4: a cohort study

Shousha¹

2022

Rev. Inst. Med. trop. S. Paulo

Self Cite

View full text Add to dashboard Cite

Despite the high sustained virologic response (SVR) rates of direct-acting antiviral (DAAs) therapy, a small number of patients does not eradicate the virus, and these patients represent a challenge. This study aims to compare the outcomes of three second-line regimens for DAAs-experienced patients with chronic hepatitis C (CHC). This prospective observational study was conducted at the Damanhur Viral Hepatitis Center from January 2017 to February 2020. We included patients with CHC who did not achieve SVR after the complete course of Sofosbuvir/Daclatasvir±Ribavirin (SOF/DAC±RBV). The primary endpoint was SVR-12 after re-treatment. This study included 360 patients (with a mean age of 51.53±11.38 years). Approximately 51.1% of the patients were males, and 65.5% had liver cirrhosis. All patients of group 1 (45 patients) received SOF/VEL/VOX over 12-weeks; SVR-12 was achieved in 44 patients (97.8%). Group 2 (28 patients) received SOF/DAC/RBV over 24-weeks; (one patient was lost during follow-ups and one patient discontinued treatment due to hepatic decompensation). SVR-12 was achieved in 25 patients (96.2%). Group 3 (287 patients) received SOF/Ombitasvir/Paritaprevir/Ritonavir/RBV) over 12-weeks. Eight patients were lost during follow-ups, and one patient discontinued treatment due to grade 4 adverse events. SVR-12 was achieved in 276 patients (99.3%). There was no difference between the groups regarding their age, gender distribution, baseline viral load or comorbidities. Adverse events (thrombocytopenia, anemia, hyperbilirubinaemia and prolonged INR) were significantly higher in group 3, while group 1 did not experience any. The three studied retreatment regimens can be used for DAAs treatment-experienced patients considering availability. The SOF/VEL/VOX combination had the least adverse events.

show abstract

“…In addition, due to the success of the Egyptian campaign for HCV elimination in Egypt [51,52], cases with chronic hepatitis C who did not receive DAAs became very small in number in the treating centers nowadays and patients who complete their treatment course and successfully eradicated the virus do not come for their follow-up, particularly old-aged patients.…”

Section: Discussionmentioning

confidence: 99%

The impact of polymorphism in PNPLA3 and TM6SF2 genes on the susceptibility and survival of hepatitis C-related hepatocellular carcinoma

Youssef

Abbas

Elfiky

et al. 2022

Egypt Liver Journal

Self Cite

View full text Add to dashboard Cite

Background Genetic variants of Patatin-like phospholipase domain-containing protein 3 (PNPLA3) and transmembrane 6 superfamily member 2 (TM6SF2) genes have been reported with the development of hepatocellular carcinoma (HCC). This study aims to explore the role of The PNPLA3 rs738409 and TM6SF2 rs58542926 single-nucleotide polymorphisms (SNPs) on the incidence and survival of HCV-induced HCC in Egyptians. Methods and results This case-control study included (120) HCC and (144) hepatitis C virus (HCV) patients. Baseline clinical, laboratory, tumor characteristics data, HCC recurrence, and overall survival were collected. PNPLA3 rs738409 and TM6SF2 rs58542926 polymorphism were detected by TaqMan allelic discrimination assay. We found that HCC patients were significantly older with male predominance. A significant difference between the TT genotypes of TM6SF2 frequency was observed in HCC compared with HCV patients. Moreover, the T allele of TM6SF2 distributions revealed a significant contribution to the different stages of HCC (p=0.03). Both PNPLA3 rs738409 and TM6SF2 rs58542926 variants showed a significant relation with treatment response according to the modified RECIST criteria. Age and diabetes mellitus were the independent factors associated with the development of HCC by multivariate regression analysis. Conclusions TM6SF2 rs58542926 polymorphism, not PNPLA3 rs738409, could be implicated in the development of HCV-induced HCC and its progression.

show abstract

Assessment of facility performance during mass treatment of chronic hepatitis C in Egypt: Enablers and obstacles

Cited by 9 publications

References 25 publications

Egypt's Ambitious Strategy to Eliminate Hepatitis C Virus: A Case Study

Egypt's Ambitious Strategy to Eliminate Hepatitis C Virus: A Case Study

Three regimens for re-treatment failure of Sofosbuvir-based therapy for chronic hepatitis-C genotype-4: a cohort study

The impact of polymorphism in PNPLA3 and TM6SF2 genes on the susceptibility and survival of hepatitis C-related hepatocellular carcinoma

Contact Info

Product

Resources

About